Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations

Cancer Genetics and Cytogenetics

Volumn 197, Issue 1, 2010, Pages 1-7

  Millecker, Laura ^a   Lennon, Patrick A ^a   Verstovsek, Srdan ^a   Barkoh, Bedia ^a   Galbincea, John ^a   Hu, Peter ^a   Chen, Su S ^a   Jones, Dan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DASATINIB; INCB 018424; JANUS KINASE 2; LENALIDOMIDE; PEGINTERFERON ALPHA2A; PHOSPHOTRANSFERASE INHIBITOR; PREDNISONE; SUNITINIB; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG; VATALANIB; XL 019;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CHROMOSOME 1; CLINICAL ARTICLE; CLINICAL FEATURE; CODON; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; GENE MUTATION; GENE NUMBER; HUMAN; HUMAN TISSUE; MYELOID METAPLASIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THROMBOCYTHEMIA; THROMBOCYTOPENIA;

CHRONIC DISEASE; CODON; DISEASE PROGRESSION; GENE DOSAGE; HUMANS; JANUS KINASE 2; KARYOTYPING; MUTATION; PRIMARY MYELOFIBROSIS; RECEPTORS, THROMBOPOIETIN; THROMBOCYTHEMIA, ESSENTIAL;

EID: 74749101243     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.10.014     Document Type: Article

References (25)

1. Vizmanos J.L., Ormazabal C., Larrayoz M.J., Cross N.C., and Calasanz M.J. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia 20 (2006) 534-535
2. Tefferi A., Lasho T.L., Schwager S.M., Steensma D.P., Mesa R.A., Li C.Y., Wadleigh M., and Gary Gilliland D. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 131 (2005) 320-328
3. Wang Y.L., Lee J.W., Kui J.S., Chadburn A., Cross N.C., Knowles D.M., and Coleman M. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals. Acta Haematol 118 (2007) 209-214
4. Kittur J., Knudson R.A., Lasho T.L., Finke C.M., Gangat N., Wolanskyj A.P., Li C.Y., Wu W., Ketterling R.P., Pardanani A., and Tefferi A. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109 (2007) 2279-2284
5. Pietra D., Li S., Brisci A., Passamonti F., Rumi E., Theocharides A., Ferrari M., Gisslinger H., Kralovics R., Cremonesi L., Skoda R., and Cazzola M. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 111 (2008) 1686-1689
6. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., and Green A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
7. Li S., Kralovics R., De Libero G., Theocharides A., Gisslinger H., and Skoda R.C. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 111 (2008) 3863-3866
8. Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa T.A., Wadleigh M., Steensma D.P., Elliott M.A., Wolanskyj A.P., Hogan W.J., McClure R.F., Litzow M.R., Gilliland D.G., and Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108 (2006) 3472-3476
9. Chaligne R., James C., Tonetti C., Besancenot R., Le Couedic J.P., Fava F., Mazurier F., Godin I., Maloum K., Larbret F., Lecluse Y., Vainchenker W., and Giraudier S. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 110 (2007) 3735-3743
10. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., Cuker A., Wernig G., Moore S., Galinsky I., DeAngelo D.J., Clark J.J., Lee S.J., Golub T.R., Wadleigh M., Gilliland D.G., and Levine R.L. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3 (2006) e270
11. Tefferi A., Thiele J., Orazi A., Kvasnicka H.M., Barbui T., Hanson C.A., Barosi G., Verstovsek S., Birgegard G., Mesa R., Reilly J.T., Gisslinger H., Vannucchi A.M., Cervantes F., Finazzi G., Hoffman R., Gilliland D.G., Bloomfield C.D., and Vardiman J.W. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110 (2007) 1092-1097
12. Thiele J., Kvasnicka H.M., Facchetti F., Franco V., van der Walt J., and Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90 (2005) 1128-1132
13. Quintas-Cardama A., Kantarjian H., Manshouri T., Luthra R., Estrov Z., Pierce S., Richie M.A., Borthakur G., Konopleva M., Cortes J., and Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27 (2009) 5418-5424
14. Quintas-Cardama A., Kantarjian H.M., Manshouri T., Thomas D., Cortes J., Ravandi F., Garcia-Manero G., Ferrajoli A., Bueso-Ramos C., and Verstovsek S. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 27 (2009) 4760-4766
15. Bojko P., Abenhardt W., Schnittger S., and Haferlach T. Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease. Onkologie 32 (2009) 191-195
16. Guglielmelli P., Pancrazzi A., Bergamaschi G., Rosti V., Villani L., Antonioli E., Bosi A., Barosi G., and Vannucchi A.M. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 137 (2007) 244-247
17. Beer P.A., Campbell P.J., Scott L.M., Bench A.J., Erber W.N., Bareford D., Wilkins B.S., Reilly J.T., Hasselbalch H.C., Bowman R., Wheatley K., Buck G., Harrison C.N., and Green A.R. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112 (2008) 141-149
18. Schnittger S., Bacher U., Haferlach C., Beelen D., Bojko P., Burkle D., Dengler R., Distelrath A., Eckart M., Eckert R., Fries S., Knoblich J., Kochling G., Laubenstein H.P., Petrides P., Planker M., Pihusch R., Weide R., Kern W., and Haferlach T. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica 94 (2009) 141-144
19. Wang X., Leblanc A., Gruenstein S., Xu M., Mascarenhas J., Panzera B., Wisch N., Parker C., Goldberg J.D., Prchal J., Hoffman R., and Najfeld V. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. Exp Hematol 37 (2009) 1194-1200
20. Douet-Guilbert N., Lai J.L., Basinko A., Gueganic N., Andrieux J., Pollet B., Plantier I., Delattre C., Crepin O., Corm S., Le Bris M.J., Morel F., and De Braekeleer M. Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome. Br J Haematol 143 (2008) 716-720
21. Douet-Guilbert N., Basinko A., Morel F., Le Bris M.J., Ugo V., Morice P., Berthou C., and De Braekeleer M. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions. Ann Hematol 87 (2008) 537-544
22. Boccuni P., MacGrogan D., Scandura J.M., and Nimer S.D. The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6). J Biol Chem 278 (2003) 15412-15420
23. Tam C.S., Abruzzo L.V., Lin K.I., Cortes J., Lynn A., Keating M.J., Thomas D.A., Pierce S., Kantarjian H., and Verstovsek S. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 113 (2009) 4171-4178
24. Hidaka T., Shide K., Shimoda H., Kameda T., Toyama K., Katayose K., Kubuki Y., Nagata K., Takenaka K., Akashi K., Okamura T., Niho Y., Mizoguchi H., Omine M., Ozawa K., Harada M., and Shimoda K. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. Eur J Haematol 93 (2009) 290-291
25. Vannucchi A.M., Antonioli E., Guglielmelli P., Longo G., Pancrazzi A., Ponziani V., Bogani C., Ferrini P.R., Rambaldi A., Guerini V., Bosi A., and Barbui T. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21 (2007) 1952-1959